To Compare the Efficacy and Safety of Misoprostol for Induction of Labour at Term Singleton Pregnancies by Intravaginal versus Sublingual Route

Authors
Ningthoujam Manganthoi Meitei¹, Namoijam Basanti², Ahanthem Sanaton³
¹,²Post Graduate Trainee, Final Year, Department of Obs & Gynae, JNIMS, Imphal, Manipur
³Professor and HOD, Department of Obs & Gynae, JNIMS, Imphal, Manipur

Abstract
Background: Induction of labour implies stimulation of contractions before the spontaneous onset of labour, with or without rupture of membranes. Common indications of labour induction include post-dated pregnancies, intra-uterine growth restriction, pregnancy induced hypertension, non-reassuring fetal status and various medical conditions such as chronic hypertension and diabetes. In routine clinical practice, there are only two classes of drugs which are seriously considered for cervical ripening and induction of labour, namely prostaglandins (E1 and E2) and oxytocin.

Materials and Method: The study was a prospective randomized study comprising of all women above 18 years with singleton term gestation in cephalic presentation with parity 1 to 3 with normal FHR and no contraindication for induction both for mother and the fetus admitted in JNIMS between October 2017 and September 2019.

Results: Delivery with a single dose was almost same in both the two groups. Normal vaginal delivery was more among intravaginal group but ventouse and LSCS was more among sublingual group but the finding was statistically insignificant. Maternal and fetal complications were comparable in between the two study groups.

Conclusion: The sublingual route of administration of misoprostol is comparable in efficacy and safety to the vaginal route for induction of labour.

Keywords: Induction, Misoprostol, Sublingual, Intravaginal.
glycosaminoglycan and hyaluronic acid and a decrease in dermatan sulfate. It can also directly increase myometrial contractility. All of these changes result in softening, effacement, and marked relaxation of the smooth muscle fibers and dilatation of the cervix. Misoprostol is extensively absorbed and rapidly metabolized, with approximately 80% excreted by the kidney with a terminal half-life of less than 1 hour when introduced vaginally and sublingually, and peak plasma levels noted at around 5-9 hours.\(^2\) It is cheap and stable at room temperature. Induction of labour has become a very popular practice in modern obstetrics, and keeping in view the various advantages and disadvantages of the different methods, the present study was undertaken to find out the safety and efficacy of vaginal versus sublingual misoprostol for induction of labour at term.

**Methodology**

The study was carried out in department of Obstetrics and Gynaecology, Jawaharlal Nehru Institute of Medical Sciences (JNIMS), Imphal, Manipur, between September 2017 to August 2019, to compare the efficacy and safety of misoprostol for induction of labour at term singleton pregnancies by intravaginal versus sublingual route with 25mcg, 3 doses at 4 hours interval. It was a prospective randomized study comprising of all women above 18 years with singleton term gestation in cephalic presentation with parity 1 to 3 with normal FHR and no contraindication for induction both for mother and the fetus. We excluded pregnant women with previous uterine surgery, cephalopelvic disproportion, women in active labour, grand multiparity, antepartum hemorrhage, twin pregnancy, preterm labour, history of cervical encirclage, malpresentation and known hypersensitivity to prostaglandins. After proper history taking, general and obstetrical examination, condition at the time of admission, during labour and mode of delivery was noted. After delivery, the mother and the babies were examined and findings was noted. Mother and babies were followed up.

**Study Tools or Procedure**

Pregnant women at term pregnancy fulfilling the inclusion criteria were admitted in the ward and the efficacy and safety of misoprostol in induction of labour by intravaginal versus sublingual route with 25mcg, 3 doses at 4 hours interval were compared. Timing of drug given, frequency of drug administration, rate of cervical dilatation, duration of first stage of labour, color of liquor, oxytocin augmentation if the induction fails after 3\(^{rd}\) dose of tablet misoprostol, mode of delivery, induction to delivery time interval, birth weight of neonates in grams, neonatal condition at birth and incidence of hyperstimulation were noted.

**Sample Size:** Based on the study of Caliskan E et al\(^3\), sample size was calculated from the following parameters:

\(\alpha=0.05\)

Power= 80% (2 sided)

Treatment effect=21%

Deliveries with 24 hours=91.3%

Sample size was found to be 60 patients in each group.

**Statistical Analysis**

Data collected were entered in Microsoft excel 2008. Data were then checked for accuracy and correctness. Data were analyzed using SPSS version 18 (statistical package for social science) and were presented in tabulated manner. Mean and percentages was used for descriptive data. For test of significance chi-square test and t – test was used. Probability value of less than 0.05 was taken as significant.
Result

Table 1: Age distribution of the respondents

| Age in years | Misoprostol Intravaginal n(%) | Misoprostol Sublingual n(%) | Total N(%) | Chi-square test |
|--------------|--------------------------------|----------------------------|------------|----------------|
| <20          | 9(15.0)                        | 10(16.6)                   | 19(15.8)   | Value=0.342, df=2, p=0.842 |
| 20-30        | 43(71.4)                       | 41(68.4)                   | 84(70.0)   |                |
| >30          | 7(11.6)                        | 9(15.0)                    | 16(13.2)   |                |
| Total        | 60(100.0)                      | 60(100.0)                  | 120(100.0) |                |

Table 1 and figure 1 show that there was a little difference in various age group. This difference was not statistically significant (p>0.05). So, both the groups were comparable regarding age. Both the mean age was also almost similar.

Table 2: Distribution of the respondents by parity

| Parity          | Misoprostol Intravaginal n(%) | Misoprostol Sublingual n(%) | Total N(%) | Chi-square test |
|-----------------|-------------------------------|----------------------------|------------|----------------|
| Primipara (1)   | 34(56.6)                      | 38(63.3)                   | 72(60.0)   | Value=0.556, df=1, p=0.455 |
| Multipara(1-2)  | 26(43.4)                      | 22(36.7)                   | 48(40.0)   |                |
| Total           | 60(100.0)                     | 60(100.0)                  | 120(100.0) |                |

Among the intravaginal group, primipara was 56.6% and among the sublingual group it was 63.3% but the difference observed was statistically insignificant as p>0.05. Parity was also comparable between the two groups.

Table 3: Distribution of the respondents by indication of induction

| Indication for induction | Misoprostol Intravaginal n(%) | Misoprostol Sublingual n(%) | Total N(%) | Chi-square test (yates corrected) |
|--------------------------|--------------------------------|----------------------------|------------|----------------------------------|
| Post term                | 28(46.6)                       | 30(50.0)                   | 58(48.4)   | Value=0.683, df=3, p=0.877      |
| Mild Oligohydranmnios    | 9(15.0)                        | 12(20.0)                   | 21(17.5)   |                |
| PROM                     | 17(28.4)                       | 15(25.0)                   | 32(26.6)   |                |
| Mild PIH                 | 6(10.0)                        | 3(5.0)                     | 9(7.5)     |                |
| Total                    | 60(100.0)                      | 60(100.0)                  | 120(100.0) |                |

Post term was the most common indication in all the cases and after stratification it was 46.6% among intravaginal group and 50% among sublingual. Mild-oligohydranmnios, PROM and mild eclampsia were almost similar among the two groups.

Table 4: Distribution of the respondents by number of doses

| Number of doses of misoprostol | Misoprostol Intravaginal n(%) | Misoprostol Sublingual n(%) | Total N(%) | Chi-square test (yates corrected) |
|-------------------------------|--------------------------------|----------------------------|------------|----------------------------------|
| One dose                      | 28(46.4)                       | 26(43.4)                   | 54(45.0)   | Value=1.273, df=2, p=0.529      |
| Two doses                     | 19(31.5)                       | 15(25.0)                   | 34(28.3)   |                |
| Three doses                   | 4(6.5)                         | 7(11.6)                    | 11(9.1)    |                |
| Induced (total)               | 51(85.0)                       | 48(80.0)                   | 99(82.5)   | Value=0.519*, df=2, p=0.471     |
| Oxytoxin augmentation*        | 9(15.0)                        | 12(20.0)                   | 20(15.7)   |                |
| Total                         | 60(100.0)                      | 60(100.0)                  | 120(100.0) |                |
Single dose was required in 46.4% of respondents among intravaginal group and in case of sublingual group it was 43.4%. And for two doses, 31.5% among intravaginal and 25% among sublingual group. Oxytocin augmentation was required in 15% among intravaginal group and 20% among sublingual group. This finding was found to be statistically insignificant (p>0.05).

Table 5: Distribution of the respondents by rate of cervical dilatation, duration of first stage

| Acceleration effect | Misoprostol Intravaginal Mean±SD | Misoprostol Sublingual Mean±SD | t-test |
|---------------------|---------------------------------|--------------------------------|--------|
| Rate of cervical dilation cm/hr | 2.66±0.80 | 2.32±0.27 | Value=3.1192 df=118 p=0.0023 |
| Duration of 1st stage in minute | 178.29±57.4 | 190±61.39 | Value=1.106 df=118 p=0.271 |
| Induction to delivery interval in minute | 496.54±94.37 | 531.64±119.98 | Value=1.78.1 df=118 p=0.077 |

Rate of dilatation was a little difference in intravaginal group (2.66±0.80 cm/hr) than sublingual group (2.32±0.27 cm/hr). This finding was statistically significant (p<0.05). Duration of 1st stage (178.29±57.4 vs. 190±61.39 minutes) and induction to delivery interval (496.54±94.37 vs. 531.64±119.98 minutes) was reduced in intravaginal group than sublingual group but found to be statistically insignificant.

Table 6: Distribution of the respondents by mode of delivery

| Mode of delivery | Misoprostol Intravaginal n(%) | Misoprostol Sublingual n(%) | Total N(%) | Chi-square test (Yates corrected) |
|------------------|------------------------------|-----------------------------|------------|----------------------------------|
| NVD (±RMLE)     | 48(80.0)                     | 43(71.6)                    | 91(75.8)   | Value=1.217 df=2 p=0.544        |
| Ventouse        | 7(11.6)                      | 9(15.0)                     | 16(13.3)   |                                   |
| LSCS            | 5(8.4)                       | 8(13.4)                     | 13(10.9)   |                                   |
| Total           | 60(100.0)                    | 60(100.0)                   | 120(100.0) |                                   |

NVD was more among intravaginal group (80% vs. 71.6%) butventouse and LSCS was more among sublingual group but the finding was statistically insignificant (p>0.05).

Table 7: Distribution of the respondents by indication of LSCS

| Indication of LSCS                  | Misoprostol Intravaginal n(%) | Misoprostol Sublingual n(%) | Total N(%) | Chi-square test (Yates corrected) |
|------------------------------------|------------------------------|-----------------------------|------------|----------------------------------|
| Fetal distress                     | 3(60.0)                      | 4(50.0)                     | 7(53.8)    | Value=0.167 df=2 p=0.919        |
| Non-progression of labour          | 1(20.0)                      | 3(37.5)                     | 4(30.7)    |                                   |
| Failure of dilatation and effacement of cervix | 1(20.0) | 1(12.5) | 2(15.5) |                                   |
| Total                              | 5(100.0)                     | 8(100.0)                    | 13(100.0)  |                                   |

Fetal distress was a bit higher among intravaginal group (60% vs. 50%), non-progression was more among sublingual group and failure of induction was more in intravaginal group. But this finding was found to be statistically insignificant.
Maternal complication was present in 11.6% of cases among intravaginal group and among sublingual group it was 15%. But the finding was statistically insignificant. Nausea and vomiting were 5% among sublingual group but among intravaginal it was 6.7%. Tachysystole was more among sublingual (5% vs 6.7%) and same finding for hyperstimulation in both the groups.

This prospective randomized control trial was conducted to compare the efficacy and safety of misoprostol for induction of labour at term by intravaginal versus sublingual route among 120 cases (60 cases each). Most of the respondents were from the age group 20-30 years and also for the two groups. So, both the groups were comparable regarding age. Parity was also comparable between the two groups. More than half of the respondents were primipara. Single dose was required in 46.4% of respondents among intravaginal group and in case of sublingual group it was 43.4%. And for two doses, 31.5% among intravaginal and 25% among sublingual group. Oxytoxin augmentation was required in 15% among intravaginal group and 20% among sublingual group. This finding was found to be statistically insignificant (p>0.05). Hissane EM et al in their study observed that there were no significant differences in the number of doses needed. Insignificant difference

### Table 8: Distribution of the respondents by maternal complications

| Maternal complications | Misoprostol Intravaginal n(%) | Misoprostol Sublingual n(%) | Total N(%) | Fisher exact test |
|------------------------|-------------------------------|----------------------------|-------------|------------------|
| Yes*                   | 7(11.6)                       | 9(15.0)                    | 16(26.6)    |                  |
| 1) Nausea and vomiting | 3(5.0)                        | 4(6.7)                     | 7(5.8)      |                  |
| 2) Tachysystole        | 3(5.0)                        | 4(6.7)                     | 7(5.8)      |                  |
| 3) Hyperstimulation    | 1(1.6)                        | 1(1.6)                     | 2(3.4)      |                  |
| No*                    | 53(88.4)                      | 51(85.0)                   | 88(88.0)    |                  |
| Total                  | 60(100.0)                     | 60(100.0)                  | 120(100.0)  |                  |

Value=0.288

\[ df=1 \]

\[ p=0.591 \]

### Table 9: Distribution of the respondents by fetal complications

| Fetal complications | Misoprostol Intravaginal n(%) | Misoprostol Sublingual n(%) | Total N(%) | Chi-square test (Yates corrected) |
|---------------------|-------------------------------|----------------------------|-------------|---------------------------------|
| Yes*                | 8(13.3)                       | 9(15.0)                    | 17(14.1)    | Value=0.0                      |
| 1) Meconium staining of liquor | 5(8.3)                       | 6(10.0)                    | 11(9.3)     | df=1                            |
| 2) Non reactive heart rate (Bradycardia) | 3(5.0)                       | 3(5.0)                     | 6(5.0)      | p-1.0                          |
| No*                 | 52(86.7)                      | 59(98.3)                   | 111(92.6)   |                                 |
| Total               | 60(100.0)                     | 60(100.0)                  | 120(100.0)  |                                 |

Value=0.0

\[ df=1 \]

\[ p-1.0 \]
was also observed in the study by Akare MD et al\textsuperscript{6} regarding risk of failed induction, reduced time from initiation to induction, reduced induction to delivery interval.

Rate of dilatation was a little difference in intravaginal group (2.66±0.80 cm/hr) than sublingual group (2.32±0.27 cm/hr). This finding was statistically significant (p<0.05). Souza AS et al\textsuperscript{7} in their study found no statistically significant difference between the sublingual and the vaginal misoprostol groups with respect to the rate of vaginal delivery within 24 hours. But duration of 1\textsuperscript{st} stage and induction to delivery interval was reduced in intravaginal group than sublingual group but found to be statistically insignificant so comparable. The mean induction to delivery time was 748 +/-379 min in the sublingual group and 711 +/- 425 min in the intravaginal group, p=0.560. So, comparable in the study by Caliskan E et al\textsuperscript{3}. Mean induction-to-delivery interval was similar in both groups (21.22 hours in the oral group vs. 20.15 hours in the vaginal group; P = 0.58).\textsuperscript{8} Mean induction delivery interval was shortest (10:35 hrs) in vaginal misoprostol group in a study undertaken to compare the safety and efficacy of intra-vaginal misoprostol, oral misoprostol and intra cervical catheter balloon for induction of labour at term in terms of interval from induction to birth, mode of delivery, maternal complication, neonatal outcome and to find out failure rate in induction of labour in all the group by Sheiker C et al\textsuperscript{9}.

NVD was more among intravaginal group (80% vs. 71.6%) but asst. Ventouse and LSCS was more among sublingual group (8.4% vs.13.3%) but the finding was statistically insignificant (p>0.05). The rate of vaginal delivery in <24 hours was higher in the vaginal group (58.6% vs 39.2%, P = .001) in the study by Haas DM et al\textsuperscript{10}. The rate of cesarean deliveries for non-re-assuring fetal status was 3.3% for the vaginal misoprostol group and 9.5% for the buccal misoprostol group (P = .033).\textsuperscript{10} In the study by Muzonzini G et al\textsuperscript{11} the buccal route was associated with a trend to fewer caesarean sections than with the vaginal route (18/73 versus 28/79; relative risk (RR) 0.70; 95% confidence interval (CI) 0.42 to 1.15).

Total induced after 3 doses was 99 (82.5%), 85% among intravaginal and 80% among sublingual. This finding was in concordance with the study by Gatta DS et al\textsuperscript{12} where labour was successfully induced in 90% of pregnant women. Seven women in the group 1 (8.8%) and 12 women in the group 2 (15%) required emergent caesarean delivery for fetal heart rate abnormalities (p=0.22) in the study by Caliskan E et al\textsuperscript{3} which is almost similar to this study. Hissane EM et al\textsuperscript{5} in their study observed vaginal delivery rates were 75% in the sublingual group and 73% in the intravaginal group.

Maternal complication was present in 11.6% of cases among intravaginal group and among sublingual group it was 15%. But the finding was statistically insignificant. Nausea and vomiting were 5% among sublingual group but among intravaginal it was 6.7%, tachysystole was more among sublingual (5% vs 6.7%) and same finding for hyperstimulation in both the groups. In the study by Souza AS et al\textsuperscript{7} it was observed there was no significant difference in uterine hyperstimulation syndrome among the two groups which was same with this study. An increased risk of uterine tachsystole was found in the sublingual misoprostol group like our study. Caliskan E et al\textsuperscript{3} in their study concluded that sublingual misoprostol is as efficacious as vaginal misoprostol for induction of labour but more frequent tachysystole is observed with sublingual misoprostol group. No statistically significant difference was found between both groups as regards the number of misoprostol doses used, need for oxytocin augmentation, mode of delivery, neonatal outcome, or the occurrence of tachysystole, hypertonus, or hyperstimulation in the study by El Kattan EA et al\textsuperscript{13}.

Out of 11 cases of meconium stained liquor, 6 of them were in sublingual group and 5 among intravaginal group. Sublingual and vaginal misoprostol had similar effectiveness; however, meconium-stained liquor was observed
considerably more frequently with sublingual misoprostol than with vaginal misoprostol in study by Jahromi BN et al\textsuperscript{14}. Late fetal heart rate deceleration was observed in 8 women in the sublingual group and 4 in the vaginal group (\textit{P}=0.22) in the above study. But fetal bradycardia was same among the two groups. Though fetal complications were more among sublingual group, it was found to be insignificant (\textit{p}>0.05). Fetal distress was same in both the cases, non-progression was more among sublingual group and failure of induction was more in intravaginal group. But this finding was found to be insignificant.

Similar finding was observed in the study by Hissane EM et al\textsuperscript{5} that there were no significant differences in the incidence of contractility disturbances, and neonatal results. The sublingual route of misoprostol was associated with a reduced risk of failed induction, reduced time from initiation to induction, reduced induction to delivery interval and a higher incidence of maternal and fetal side effects which was a bit contradictory to this study. However, the differences were not statistically significant. The sublingual route of administration of misoprostol is comparable in efficacy and safety to the vaginal route for induction.

**Conclusion**

Induction of labour is usually performed when the risks of continuing pregnancy are higher than the benefits of delivery. A prospective randomised control trial was conducted to compare the efficacy and safety of misoprostol for induction of labour at term by intravaginal versus sublingual route with single live fetus (25mcg, 3 doses at 4 hours interval) among 120 cases (60 cases each) in the department of Obs and Gynae, JNIMS, Imphal. Age, address, parity and booked status were comparable between the study groups. Delivery with a single dose was almost same in both the two groups. Oxytocin augmentation though little more among sublingual group was statistically insignificant. Rate of dilatation was significantly more among intravaginal group but the induction of delivery and mean 1\textsuperscript{st} stage of labour was insignificant. Normal vaginal delivery (NVD) was more among intravaginal group but ventouse and LSCS was more among sublingual group but the finding was statistically insignificant. Maternal and fetal complications were comparable in between the two study groups. The sublingual route of administration of misoprostol is comparable in efficacy and safety to the vaginal route for induction. Further study with a bigger sample is recommended to a robust significant finding.

**References**

1. Cunningham FG, Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, et al, editors. William Obstetrics. 24\textsuperscript{th} edition. New York: Mc Graw- Hill; 2014.
2. Stephenson ML, Wing DA. A novel misoprostol delivery system for induction of labour. Drug Des Devel Ther 2015;9(1):2321-7.
3. Caliskan E, Bodur H, Ozeren S, Corakei A, Ozkan S, Yucesoy I, Misoprostol 50 mcg sublingually versus vaginally for labour induction at term. Gynaecol Obstet Invest 2005;59(3):155-61.
4. Fletcher HM, Mitchell S, Simeon D, Freidrick J, Brown D: Misoprostol for labor induction at term. Br J Obstet Gynaecol. 1993;100:641-4.
5. Hassane EM, El Karroumi M, Mikou F, Ghazil M. Misopristol sublingual versus vaginally for induction of labour at term. Res ObstetGynaecol 2012;1(3):279-83.
6. Akare MD, Patel PK. A comparison of sublingual with vaginal administration of misoprostol for induction of labor at term. Int J Reprod Contracept Obstet Gynecol 2017;6:1398-403
7. Souza AS, Amorim M, Feitosa F. Comparison of sublingual versus vaginal misoprostol for the induction of labour. Int J Obstet Gynaecol 2008;115(1):1340-9
8. Rahman H, Pradhan A, Kharta L, Renjhen P, Kar S, Dutta S. Comparative Evaluation of 50 Microgram Oral Misoprostol and 25 Microgram Intravaginal Misoprostol for Induction of Labour at Term: A Randomized Trial. Journal of Obstetrics and Gynaecology Canada 2013 May;35(5):408-16.

9. Sheikher C, Suri N, Kholi U. Comparative Evaluation of Oral Misoprostol, Vaginal Misoprostol and Intracervical Folley’s Catheter for Induction of Labour at Term. JKScience. 2009;11(2):75-78. Sharami SH, Milani F, Faraji R, Bloukimoghadam K, Salamat F, Momenzade S, et al. Comparison of 25 mcg sublingual and 50 mcg intravaginal misoprostol for cervical ripening and labour. Arch Iran Med 2014;17(10):652-6.

10. Haas DM, Daggy J, Flannery KM, Dorr ML, Bonsack C, Bhamidipalli SS, Pierson RC, Lathrop A, et al. A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial. Am J Obstet Gynecol. 2019;211(3):259.e1-259.e16.

11. Muzonzini G, Hofmeyr GJ. Buccal or sublingual misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004221.

12. Gattas DS, Souza AS, Florentino AV, Nobrega BV, Fook VP, et al. Low dose of sublingual misoprostol 12.5 mcg for labour induction. Rev Bras GynaecolObstet 2012;34(4):164-9.

13. El Kattan AE, Moety GAA, AbdEirazek AA. Sublingual versus vaginal misoprostol for induction of labor in term primigravida: a randomized study. Evid Based Women Health J. 2013;3(2):111–4.

14. Jahromi NB, Poorgholam F, YousefiGhH, Salarian L. Sublingual versus Vaginal Misoprostol for the Induction of Labor at Term: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. Iran J Med Sci. 2016;41(2):79-85.

15. Malik HZ, Khawaja NP, Zahib B, Rehman R. Sublingual versus vaginal misoprostol for induction of labour at term. J coll physicians Surg Pak 2010;20(9):242-5.

16. Ayati S, Vahidroodsari F, Farshidi F, Shahhabian M, Afzal Aghae M. Vaginal versus sublingual misoprostol for labour induction at term and post term. Iran J Pharm Res 2014;13(1):299-304.